for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Organicell Regenerative Medicine Inc

BPSR.PK

Latest Trade

0.10USD

Change

0.00(+1.70%)

Volume

1,260,121

Today's Range

0.10

 - 

0.12

52 Week Range

0.04

 - 

0.63

As of on the Over The Counter ∙ Minimum 15 minute delay

Latest Developments

Organicell Begins Up-Listing Process On Nasdaq

May 4 (Reuters) - Organicell Regenerative Medicine Inc <BPSR.PK>::ORGANICELL BEGINS UP-LISTING PROCESS ON NASDAQ EXCHANGE.ORGANICELL REGENERATIVE MEDICINE - CURRENTLY EXPLORING OPTIONS TO UP-LIST ITS COMMON STOCK TO NASDAQ CAPITAL MARKET TIER OF NASDAQ STOCK MARKET, LLC..

Organicell Announces Positive Results Of Initial Covid-19 Zofin™ Patient Trial In India And Trial Expansion

April 28 (Reuters) - Organicell Regenerative Medicine Inc <BPSR.PK>::ORGANICELL ANNOUNCES POSITIVE RESULTS OF INITIAL COVID-19 ZOFIN™ PATIENT TRIAL IN INDIA AND TRIAL EXPANSION.ORGANICELL REGENERATIVE MEDICINE INC - ANNOUNCED POSITIVE RESULTS FOR FIRST TEN COVID-19 PATIENTS TREATED WITH ZOFIN IN INDIA.ORGANICELL REGENERATIVE MEDICINE INC - ALL PATIENTS UNDER TRIAL HAVE RECOVERED FROM THEIR SYMPTOMS AND HAVE SINCE BEEN DISCHARGED FROM HOSPITAL.ORGANICELL REGENERATIVE - BASED ON INITIAL RESULTS OF TRIAL, TRIAL WILL BE EXPANDED TO ADDITIONAL SIXTY-FIVE PATIENTS WITH MODERATE TO SEVERE COVID-19.ORGANICELL - IF RESULTS OF EXPANDED TRIAL ARE SIMILARLY POSITIVE, INTEND TO FILE FOR EUA TO USE ZOFIN IN INDIA AS THERAPEUTIC FOR TREATING COVID-19.

Organicell Announces FDA Approval Of IND Application For Use Of Zofin In The Treatment Of Chronic Obstructive Pulmonary Disease

Jan 28 (Reuters) - Organicell Regenerative Medicine Inc <BPSR.PK>::ORGANICELL ANNOUNCES FDA APPROVAL OF IND APPLICATION FOR THE USE OF ZOFIN™ IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).

Organicell Regenerative Medicine - FDA Granted Emergency, Expanded Access Approval To Treat 2 Mild To Moderate Covid-19 Patients

Sept 2 (Reuters) - Organicell Regenerative Medicine Inc <BPSR.PK>::ORGANICELL REGENERATIVE MEDICINE - FDA GRANTED EMERGENCY, EXPANDED ACCESS APPROVAL TO TREAT 2 MILD TO MODERATE COVID-19 PATIENTS.ORGANICELL REGENERATIVE MEDICINE - FDA GRANTED EMERGENCY, EXPANDED ACCESS APPROVAL TO TREAT 1 "LONG HAULER" POST COVID-19 PATIENT.ORGANICELL REGENERATIVE MEDICINE - 6 OUTPATIENTS WITH DIFFERENT STAGES OF COVID-19 WERE TREATED WITH ZOFIN REPORTING SIGNIFICANT IMPROVEMENT.ORGANICELL REGENERATIVE MEDICINE - WILL CONSIDER EXPANDING ZOFIN MANUFACTURING CAPABILITY, IF POSITIVE PATIENT RESULTS CONTINUE.ORGANICELL - TO COMMENCE PATIENT ENROLLMENT THIS WEEK IN PHASE I/II CLINICAL TRIAL TO EVALUATE TREATMENT OF ZOFIN IN MODERATE TO SEVERE COVID-19 PATIENTS.

Organicell Announces FDA Approval Of Ind Application For The Treatment Of Sars Due To Covid-19

May 5 (Reuters) - Organicell Regenerative Medicine Inc <BPSR.PK>::ORGANICELL ANNOUNCES FDA APPROVAL OF IND APPLICATION FOR THE TREATMENT OF SARS DUE TO COVID-19.

Bespoke Tricycles Inc enters into stock purchase agreement - Form 8-K

Bespoke Tricycles Inc:Says On May 29, entered into a stock purchase agreement with John Goodhew and Albert Mitrani.Pursuant to the terms of the Purchase Agreement, Mitrani agreed to purchase 7,500,000 shares of common stock, representing all of the shares of common stock held by Goodhew.Purchase price for the Shares, which represent 87.8 pct of the issued and outstanding shares of common stock on a fully diluted basis, of $40,000, is payable by Mitrani to Goodhew no later than twelve months from the closing date.

Bespoke Tricycles Inc announces change in independent registered public accounting firm - Form 8-K

Bespoke Tricycles Inc:Says on Aug. 4, Silberstein Ungar, PLLC (Former Accountant) notified company that its principals joined accounting firm of KLJ & Associates, LLP.As a result of transaction, on Aug. 4, Former Accountant resigned as company’s independent registered public accounting firm.Company engaged KLJ & Associates, LLP (New Accountant) as company’s independent registered public accounting firm.

Bespoke Tricycles Inc announces initial public offering

Bespoke Tricycles Inc:Offers 4,000,000 shares with share price of $0.05 as initial public offer.Total offer amount is $200,000.Offering is a self-underwritten offering.Net proceeds are used for commissions, facility, materials and equipment, advertising and marketing, labor and legal and accounting.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up